Xeno Nucleic Acids: Design, Synthesis, and Applications

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Xeno Nucleic Acids

What Are XNAs?

Xeno nucleic acids (XNAs) are synthetic genetic polymers in which the natural ribofuranose or deoxyribofuranose sugar backbone of DNA and RNA is replaced with an alternative chemical scaffold. The term "xeno" derives from the Greek xenos, meaning foreign or strange, reflecting the non-natural nature of these polymers. While the nucleobases—adenine, guanine, cytosine, thymine, and uracil—are typically retained, the sugar-phosphate backbone is modified to confer novel properties such as enhanced nuclease resistance, altered duplex geometry, or orthogonal base-pairing behavior.

The conceptual foundation of XNA research rests on the recognition that the canonical DNA and RNA nucleic acids represent only two solutions to the requirements of information storage and transfer. The genetic alphabet, the sugar chemistry, and the phosphodiester linkage are all parameters that can be varied. XNAs expand the chemical space of heredity, allowing researchers to ask fundamental questions about the origins of life while simultaneously engineering polymers with practical utility in biotechnology and medicine.

Why Engineer XNAs?

The motivations for engineering XNAs are both fundamental and applied. From a basic science perspective, XNAs test the hypothesis that nucleic acid-based life is not chemically inevitable—that alternative backbones can support information storage, replication, and evolution. The successful synthesis and evolution of XNAs demonstrate that the genetic system is more plastic than previously assumed.

From an applied perspective, XNAs offer several advantages over natural nucleic acids. First, the non-natural backbone typically renders XNAs resistant to nucleases that rapidly degrade DNA and RNA in biological fluids, a critical property for therapeutic applications. Second, XNAs can be designed to bind targets with high affinity and specificity, functioning as aptamers. Third, because XNAs do not interact with the cellular machinery that processes DNA and RNA, they exhibit reduced off-target effects in therapeutic contexts. Finally, XNAs represent a potential medium for long-term data storage, as their resistance to enzymatic degradation and chemical hydrolysis exceeds that of DNA.

This article provides a comprehensive overview of XNA research, covering backbone chemistry, chemical and enzymatic synthesis, structural properties, directed evolution, and applications. The focus throughout is on mechanistic detail and practical methodology.

Chemical Diversity of XNA Backbones

Sugar-Modified XNAs

The most extensively studied XNAs are those in which the furanose ring is modified. These modifications alter the sugar pucker, the orientation of the 3'- and 5'-substituents, and the overall helical geometry of the resulting duplex.

1',5'-Anhydrohexitol nucleic acids (HNA): HNA contains a six-membered hexitol ring in place of the five-membered ribose. The hexitol ring adopts a chair conformation, positioning the nucleobase equatorially and the phosphodiester linkages axially. This geometry results in a duplex that is more rigid than B-form DNA, with a wider major groove. HNA hybridizes with complementary RNA with high affinity but shows weaker binding to DNA, a property that has been exploited in antisense applications.

Threose nucleic acids (TNA): TNA is built from α-L-threofuranosyl units, a four-carbon sugar that is a diastereomer of ribose. Despite having only three carbons between adjacent phosphates (instead of the four in DNA and RNA), TNA forms antiparallel duplexes with complementary DNA, RNA, and TNA strands. The TNA-TNA duplex adopts an A-form-like geometry. The remarkable ability of TNA to cross-pair with natural nucleic acids has made it a leading candidate for studies of prebiotic chemistry and for the development of stable antisense agents.

Locked nucleic acids (LNA): LNA is a ribonucleotide analog in which a methylene bridge connects the 2'-oxygen and the 4'-carbon of the ribose ring. This "locking" constrains the sugar to the C3'-endo (RNA-like) pucker, pre-organizing the nucleotide for duplex formation. LNA monomers, when incorporated into DNA or RNA oligonucleotides, dramatically increase melting temperatures (Tm) by 2–8 °C per modification. LNA is not strictly an XNA in the sense of being a fully substituted backbone; rather, it is typically used as a modification within otherwise natural oligonucleotides.

2'-Fluoroarabino nucleic acids (FANA): FANA contains arabinose, the 2'-epimer of ribose, with a fluorine atom at the 2'-position. The fluorine substituent is in the arabino configuration (pointing "up" relative to the ring), which biases the sugar toward the C2'-endo (DNA-like) pucker. FANA oligonucleotides exhibit high nuclease resistance and can recruit RNase H when hybridized to RNA, making them useful for antisense applications.

Cyclohexene nucleic acids (CeNA): CeNA incorporates a cyclohexene ring in place of the furanose. The cyclohexene ring is conformationally flexible but introduces a rigid double bond that restricts rotation. CeNA-RNA duplexes are recognized by RNase H, and CeNA oligonucleotides show enhanced serum stability.

Phosphodiester Linkage Variants

Beyond sugar modifications, the phosphodiester linkage itself can be altered. These changes affect the charge, polarity, and susceptibility to nucleases.

Phosphorothioate linkages: In phosphorothioate (PS) oligonucleotides, one of the non-bridging phosphate oxygens is replaced with sulfur. This modification confers nuclease resistance and enhances protein binding, but it introduces a chiral center at phosphorus, producing Rp and Sp diastereomers. PS-modified oligonucleotides are widely used in antisense therapeutics, although the stereochemistry must be controlled for optimal activity.

Phosphoramidate linkages: In phosphoramidates, one of the non-bridging oxygens is replaced with a nitrogen-containing group. The morpholino phosphoramidate (PMO) class, in which the sugar is replaced with a morpholine ring and the phosphodiester is replaced with a phosphorodiamidate linkage, is notable for its exceptional nuclease resistance and its ability to block translation by steric hindrance.

Methylphosphonate linkages: Replacing a non-bridging oxygen with a methyl group eliminates the negative charge of the backbone. Methylphosphonate oligonucleotides are uncharged, which reduces electrostatic repulsion during hybridization but also decreases aqueous solubility.

Peptide Nucleic Acids

Peptide nucleic acids (PNA) represent a radical departure from sugar-based backbones. In PNA, the entire sugar-phosphate backbone is replaced with a repeating N-(2-aminoethyl)glycine unit linked by amide bonds. The nucleobases are attached to the glycine nitrogen via methylene carbonyl linkers. PNA is uncharged, achiral, and synthesized by standard solid-phase peptide chemistry.

PNA hybridizes with complementary DNA and RNA with high affinity and sequence specificity, forming duplexes that are more stable than the corresponding DNA-DNA or DNA-RNA duplexes. The uncharged backbone eliminates electrostatic repulsion, and the flexible linker allows optimal base stacking. PNA is resistant to both nucleases and proteases, making it exceptionally stable in biological systems. However, PNA's poor cellular uptake and limited aqueous solubility have constrained its therapeutic development.

Synthesis of XNA Monomers and Oligomers

Monomer Synthesis

The synthesis of XNA phosphoramidite monomers is the foundational step for solid-phase oligonucleotide synthesis. The general strategy involves protecting the nucleobase exocyclic amines, the 5'-hydroxyl (or equivalent), and the phosphate moiety, while leaving the 3'-hydroxyl (or equivalent) available for coupling.

For sugar-modified XNAs, the synthetic route typically begins with the appropriate sugar precursor. For HNA, the hexitol ring is prepared from glucose or from a Diels-Alder cycloaddition, followed by introduction of the nucleobase via a Vorbrüggen glycosylation. For TNA, the threose sugar is synthesized from L-ascorbic acid or from tartaric acid derivatives. The glycosylation step is often challenging due to the steric environment of the four-membered ring precursors and typically requires careful optimization of the Lewis acid catalyst (e.g., trimethylsilyl triflate) and reaction temperature.

For LNA, the key step is the introduction of the 2'-O,4'-C-methylene bridge. This is achieved by treating a 2'-hydroxyl ribonucleoside with a suitable leaving group at the 4'-position under basic conditions, promoting intramolecular cyclization. The resulting bicyclic nucleoside is then converted to the phosphoramidite.

For FANA, the 2'-fluoro group is introduced by nucleophilic fluorination of a 2'-hydroxyl arabinonucleoside using diethylaminosulfur trifluoride (DAST) or by opening of a 2,2'-anhydro intermediate with fluoride ion.

For PNA, monomers are synthesized by coupling the appropriate nucleobase acetic acid to the secondary amine of N-(2-Boc-aminoethyl)glycine, followed by activation of the carboxylate for subsequent coupling.

Solid-Phase Oligonucleotide Synthesis

XNA oligomers are assembled on controlled pore glass (CPG) or polystyrene supports using standard phosphoramidite chemistry, with modifications to accommodate the unique properties of each XNA.

The synthesis cycle consists of four steps:

1. Detritylation: Removal of the 5'-O-dimethoxytrityl (DMT) group with 3% trichloroacetic acid in dichloromethane.
2. Coupling: Activation of the incoming phosphoramidite with 5-ethylthio-1H-tetrazole (ETT) or 4,5-dicyanoimidazole (DCI), followed by condensation with the free 5'-hydroxyl. The coupling time must be optimized for each XNA monomer; for sterically hindered monomers such as TNA and LNA, coupling times of 10–30 minutes are common, compared to 2–5 minutes for standard DNA.
3. Capping: Acetylation of unreacted 5'-hydroxyl groups with acetic anhydride and N-methylimidazole to prevent the accumulation of deletion sequences.
4. Oxidation: Conversion of the phosphite triester to the phosphate triester using 0.02 M iodine in tetrahydrofuran/pyridine/water. For phosphorothioate linkages, the oxidation step is replaced with sulfurization using 3-((dimethylaminomethylidene)amino)-3H-1,2,4-dithiazole-3-thione (DDTT).

After chain assembly, the oligomer is cleaved from the support and deprotected. For standard DNA/RNA, this involves treatment with concentrated ammonium hydroxide at 55 °C for 8–16 hours. For XNAs containing acid-labile or base-sensitive modifications, gentler conditions may be required. For example, FANA oligomers are typically deprotected with ammonium hydroxide at room temperature to minimize elimination of the 2'-fluoro group.

A major challenge in XNA solid-phase synthesis is the reduced coupling efficiency observed for many modified monomers. While standard DNA synthesis achieves coupling efficiencies above 99%, some XNA monomers couple at 95–98% efficiency, limiting the maximum accessible oligomer length to approximately 50–80 nucleotides. This limitation has motivated the development of enzymatic synthesis methods, described below.

Enzymatic Synthesis and Replication of XNAs

Engineering Polymerases for XNA Synthesis

Natural polymerases are highly specific for their cognate substrates—DNA polymerases for deoxyribonucleoside triphosphates (dNTPs) and RNA polymerases for ribonucleoside triphosphates (NTPs). The incorporation of XNA triphosphates (XNTPs) by wild-type polymerases is typically extremely inefficient, with incorporation efficiencies (kcat/Km) reduced by 10⁴- to 10⁶-fold compared to natural substrates. This specificity arises from multiple checkpoints, including the steric gate residue (typically a bulky aromatic amino acid in the active site that excludes 2'-substituents), the geometry of the nascent base pair, and the conformational change that accompanies nucleotide binding.

To overcome this barrier, polymerases are engineered using directed evolution. The general strategy involves:

1. Random mutagenesis of a polymerase gene, typically using error-prone PCR or DNA shuffling.
2. Selection or screening for variants that can incorporate XNTPs.

For the thermostable DNA polymerase from Thermus aquaticus (Taq), mutations at the steric gate residue (e.g., G669A) and in the fingers domain have been shown to relax substrate specificity. More extensive engineering has produced variants such as the "SFM4-3" polymerase, which can synthesize HNA, TNA, FANA, and other XNAs with reasonable efficiency.

The selection strategy often employs a primer extension assay in which a DNA primer is extended on a DNA template in the presence of XNTPs. Active variants are identified by the incorporation of a labeled XNTP or by the production of full-length product. For more demanding applications, such as the replication of XNA templates, polymerases must also be able to read XNA templates and incorporate natural dNTPs or NTPs opposite XNA bases. This requires additional mutations that allow the polymerase to accommodate the altered geometry of the XNA template strand.

XNA Replication and Evolution

The ultimate goal of XNA research is the establishment of XNA-based systems capable of Darwinian evolution. This requires the ability to copy XNA into XNA, either directly or through a DNA intermediate.

For most XNAs, direct XNA-to-XNA replication is inefficient. Instead, a two-step process is used:

1. XNA synthesis from a DNA template: A DNA template is copied into XNA using an engineered polymerase and XNTPs.
2. XNA reverse transcription: The XNA strand is copied back into DNA using a reverse transcriptase variant that can read XNA templates.

This "DNA→XNA→DNA" cycle enables the amplification of XNA sequences using standard PCR, with the XNA serving as a transient information carrier. The fidelity of this process is critical. For the best engineered polymerase systems, error rates of approximately 10⁻³ to 10⁻⁴ per base per replication cycle have been reported, which is higher than the error rate of natural DNA replication (10⁻⁹ to 10⁻¹⁰) but sufficient for in vitro evolution experiments.

The development of polymerases capable of direct XNA-to-XNA replication remains an active area of research. Such polymerases would enable the continuous evolution of XNA molecules without the need for a DNA intermediate, more closely mimicking natural genetic systems.

Structural and Biophysical Properties of XNAs

Duplex Stability and Thermodynamics

The thermal stability of XNA duplexes varies widely depending on the backbone chemistry. Several factors contribute to duplex stability:

Sugar pucker and pre-organization: LNA monomers are pre-organized in the C3'-endo conformation, reducing the entropic cost of duplex formation. This explains the dramatic Tm increases observed for LNA-modified oligonucleotides. Conversely, flexible backbones such as PNA exhibit high duplex stability due to the absence of electrostatic repulsion between the uncharged backbones.

Hydration and electrostatic effects: The negatively charged phosphodiester backbone of sugar-based XNAs creates electrostatic repulsion that destabilizes duplex formation. The addition of monovalent cations (typically 100–150 mM NaCl or KCl) screens this repulsion. PNA, being uncharged, does not require high salt concentrations for stable duplex formation.

Base stacking: The geometry of the backbone influences the overlap of adjacent nucleobases. XNAs that enforce a more vertical base arrangement, such as HNA and LNA, exhibit enhanced stacking interactions.

Typical Tm values for 15-mer duplexes under standard conditions (100 mM NaCl, 10 mM phosphate, pH 7.0) are approximately 50–60 °C for DNA-DNA, 60–70 °C for DNA-RNA, and 70–80 °C for LNA-DNA or PNA-DNA duplexes. The table below summarizes the properties of selected XNAs.

Structural Analysis by Crystallography and NMR

High-resolution structures of XNA duplexes have provided insight into the structural basis of their properties.

HNA duplex structure: The crystal structure of an HNA duplex revealed a right-handed helix with a wide, shallow major groove and a narrow minor groove. The hexitol rings adopt a chair conformation, and the phosphodiester backbone is extended relative to DNA. The helix has a rise of approximately 3.4 Å per base pair and a twist of approximately 30°, similar to B-form DNA, but the overall geometry is more rigid.

TNA duplex structure: The structure of a TNA-TNA duplex showed an A-form-like geometry with C3'-endo sugar pucker. Despite the reduced number of backbone atoms, the TNA duplex maintains standard Watson-Crick base pairing with a helical rise of 2.8 Å and a twist of 32°. The backbone adopts a "crankshaft" conformation that allows the phosphates to be positioned similarly to those in RNA.

FANA duplex structure: FANA-RNA duplexes adopt an A-form geometry, while FANA-DNA duplexes are intermediate between A- and B-form. The 2'-fluoro substituent in the arabino configuration points toward the minor groove, where it can participate in hydrogen bonding with water molecules.

PNA duplex structure: The PNA-DNA duplex structure revealed a unique geometry in which the PNA strand adopts a helical conformation with the nucleobases positioned for Watson-Crick pairing. The amide backbone is more flexible than the sugar-phosphate backbone, allowing PNA to adapt to the geometry of its complement.

Directed Evolution of XNA Aptamers and Catalysts

In Vitro Selection of XNA Aptamers

The selection of XNA aptamers follows the same general principles as SELEX (Systematic Evolution of Ligands by EXponential enrichment) for DNA and RNA aptamers, with modifications to accommodate the enzymatic synthesis and reverse transcription steps.

The selection cycle consists of the following steps:

1. Library construction: A DNA library containing a randomized region (typically 30–50 nucleotides) flanked by fixed primer-binding sites is synthesized. The library complexity is typically 10¹⁴–10¹⁵ molecules.
2. XNA synthesis: The DNA library is transcribed into XNA using an engineered polymerase and XNTPs.
3. Selection: The XNA library is incubated with the target of interest. Target-bound XNA molecules are separated from unbound molecules by affinity capture (e.g., on magnetic beads or a chromatography resin).
4. Reverse transcription: The selected XNA molecules are reverse-transcribed into DNA using an engineered reverse transcriptase.
5. Amplification: The recovered DNA is amplified by PCR, and the cycle is repeated.

After 6–12 rounds of selection, individual clones are isolated and characterized. The success of XNA aptamer selection depends critically on the fidelity of the polymerase system; errors introduced during XNA synthesis or reverse transcription will accumulate over successive rounds and compromise the integrity of the selected sequences.

XNA aptamers have been selected against a variety of targets, including proteins, small molecules, and even whole cells. The resulting aptamers typically exhibit dissociation constants (Kd) in the low nanomolar to picomolar range, comparable to or better than equivalent DNA or RNA aptamers. The enhanced nuclease resistance of XNA aptamers makes them attractive for therapeutic and diagnostic applications.

Isolation of XNAzymes

XNAzymes are XNA molecules with catalytic activity. The isolation of XNAzymes requires a selection strategy that links catalytic activity to survival or amplification.

One approach is in vitro compartmentalization (IVC) . In this method, XNA molecules are compartmentalized in water-in-oil emulsions, with each droplet containing a single XNA molecule, its encoded product, and the components needed for reverse transcription and PCR. Catalytically active XNAzymes modify their own or a linked substrate, enabling their selective amplification.

A second approach is cis-selection, in which the XNAzyme is covalently linked to its substrate. Cleavage of the substrate releases the XNAzyme, which can then be reverse-transcribed and amplified. This approach has been used to isolate RNA-cleaving XNAzymes.

The first XNAzymes were RNA-cleaving enzymes based on FANA and HNA backbones. These enzymes exhibit Michaelis-Menten kinetics with kcat values of approximately 0.1–1 min⁻¹ and Km values in the nanomolar range. While less active than natural protein ribonucleases, XNAzymes demonstrate that catalytic function can be encoded in non-natural backbones.

Applications of XNAs in Biotechnology and Medicine

Therapeutic Applications

Antisense oligonucleotides: XNAs are promising antisense agents because of their nuclease resistance and high binding affinity. LNA-modified gapmers (oligonucleotides containing a central DNA region flanked by LNA nucleotides) are in clinical development for the treatment of genetic diseases. These gapmers recruit RNase H to cleave the target mRNA, while the LNA flanks protect the oligonucleotide from degradation. FANA antisense oligonucleotides also recruit RNase H and have shown efficacy in preclinical models.

Aptamer therapeutics: XNA aptamers that bind to therapeutic targets with high affinity and specificity are being developed as antagonists of disease-associated proteins. The enhanced stability of XNA aptamers in serum and their lack of immunogenicity make them attractive alternatives to protein-based biologics.

siRNA and miRNA modulation: LNA-modified siRNAs exhibit enhanced thermal stability and nuclease resistance. LNA antimiRs (anti-microRNA oligonucleotides) are being developed for the treatment of diseases associated with microRNA dysregulation.

Diagnostic Tools

Molecular beacons: XNA-modified molecular beacons, which fluoresce upon hybridization to a complementary target, are used for the detection of specific nucleic acid sequences. The enhanced binding affinity of LNA and PNA beacons allows the detection of single-nucleotide polymorphisms with high specificity.

Biosensors: XNA aptamers immobilized on surfaces (e.g., gold nanoparticles, electrodes, or microarrays) can detect protein or small-molecule targets with high sensitivity. The stability of XNAs allows their use in complex biological matrices such as serum or saliva.

Data Storage

The information density of nucleic acids (theoretically up to 2 bits per nucleotide) and their stability over long time scales make them attractive for data storage. XNAs offer advantages over DNA for this application:

• Enhanced chemical stability: The non-natural backbone is resistant to hydrolysis and oxidation.
• Reduced contamination risk: XNAs are not recognized by natural DNA repair and replication machinery, reducing the risk of unintended amplification or degradation.
• Orthogonal information channels: The use of multiple XNA backbones could allow parallel data storage in the same physical space.

The synthesis of XNA oligomers for data storage is currently limited by the cost and efficiency of solid-phase synthesis. However, the development of enzymatic XNA synthesis methods may eventually enable cost-effective, large-scale XNA data storage.

Common Pitfalls and Practical Considerations

Solubility and Handling

Problem: Many XNAs, particularly those with hydrophobic modifications (e.g., LNA, CeNA) or uncharged backbones (PNA), exhibit poor aqueous solubility.

Solutions:

• Use low-salt buffers (10–50 mM Tris or phosphate buffer) to avoid salting-out effects.
• For PNA, dissolve in a minimal volume of dimethyl sulfoxide (DMSO) or dimethylformamide (DMF) before diluting into aqueous buffer.
• For hydrophobic XNAs, add a non-ionic detergent such as Tween-20 (0.01–0.1%) to the buffer.
• Store XNA oligomers as lyophilized powders at –20 °C; avoid repeated freeze-thaw cycles of solutions.

Fidelity and Error Rates

Problem: The fidelity of XNA synthesis and reverse transcription is lower than that of natural DNA replication, leading to the accumulation of mutations during selection experiments.

Solutions:

• Minimize the number of amplification cycles during selection.
• Use high-fidelity polymerase variants when available.
• Sequence individual clones after selection to assess the mutation load.
• For aptamer selections, consider using a "doped" library in later rounds to maintain sequence diversity while enriching for active variants.

Choosing the Right XNA

Problem: The choice of XNA backbone depends on the intended application, and no single XNA is optimal for all purposes.

Considerations:

• For antisense applications requiring RNase H activation: FANA or CeNA.
• For high-affinity hybridization with minimal length: LNA or PNA.
• For nuclease resistance in biological fluids: HNA, TNA, or PNA.
• For compatibility with enzymatic synthesis and evolution: HNA, TNA, or FANA (all have well-characterized polymerase systems).
• For structural biology studies: TNA (crystallizes well) or HNA (rigid, well-defined geometry).

Nuclease Resistance Misinterpretation

Problem: The assumption that all XNAs are completely resistant to nucleases is incorrect. Some XNAs are degraded by specific nucleases, and resistance depends on the enzyme and the context.

Solutions:

• Test nuclease resistance empirically in the relevant biological matrix (e.g., serum, cell lysate) rather than relying on published data.
• Include appropriate controls (e.g., a DNA oligonucleotide of the same sequence) in nuclease assays.
• For therapeutic applications, consider additional modifications (e.g., phosphorothioate linkages) to enhance stability.

Frequently Asked Questions

What are xeno nucleic acids?

Xeno nucleic acids (XNAs) are synthetic genetic polymers in which the sugar-phosphate backbone of natural DNA and RNA is replaced with an alternative chemical structure. The nucleobases are typically retained, allowing XNAs to hybridize with natural nucleic acids through Watson-Crick base pairing. XNAs are designed to exhibit properties such as enhanced nuclease resistance, altered duplex geometry, and orthogonal behavior relative to natural nucleic acids.

How are xeno nucleic acids synthesized?

XNAs are synthesized by two complementary approaches. Chemically, XNA phosphoramidite monomers are assembled into oligomers using solid-phase oligonucleotide synthesis, which involves repeated cycles of deprotection, coupling, capping, and oxidation. Enzymatically, engineered polymerases incorporate XNA triphosphates onto a DNA template, enabling the synthesis of longer XNA polymers and the amplification of XNA sequences through a DNA intermediate.

Can xeno nucleic acids replicate?

Yes, XNAs can replicate, but not by natural polymerases. Engineered polymerases, obtained through directed evolution, can synthesize XNA from a DNA template and reverse-transcribe XNA back into DNA. This DNA→XNA→DNA cycle allows the amplification of XNA sequences using standard PCR. Direct XNA-to-XNA replication has been demonstrated for some XNAs but remains less efficient than the two-step process.

What are the applications of xeno nucleic acids?

XNAs have applications in therapeutics (antisense oligonucleotides, aptamers, siRNA modulation), diagnostics (molecular beacons, biosensors), and data storage. Their nuclease resistance and high binding affinity make them particularly attractive for in vivo applications where natural nucleic acids are rapidly degraded.

Are xeno nucleic acids stable in biological systems?

Most XNAs exhibit significantly enhanced stability in biological fluids compared to DNA and RNA, due to the non-natural backbone being poorly recognized by nucleases. However, stability varies among XNAs and depends on the specific nuclease and biological context. Empirical testing in the relevant biological matrix is recommended.

What is the difference between XNA and DNA?

The primary difference is the backbone. DNA contains 2'-deoxyribose sugars linked by phosphodiester bonds, while XNAs contain alternative sugars (e.g., hexitol, threose, locked ribose) or entirely different backbones (e.g., peptide nucleic acid). XNAs typically exhibit enhanced nuclease resistance and altered duplex stability compared to DNA, but they may also have reduced compatibility with natural enzymes.

How are XNA polymerases engineered?

XNA polymerases are engineered through directed evolution. The polymerase gene is randomly mutagenized, and the resulting library is screened for variants that can incorporate XNA triphosphates or read XNA templates. Key mutations often occur in the steric gate residue and the fingers domain of the polymerase, which normally exclude non-cognate substrates. Multiple rounds of mutation and selection are typically required to obtain polymerases with sufficient activity and fidelity.

Key Takeaways

• Xeno nucleic acids (XNAs) are synthetic genetic polymers with alternative backbones that retain the nucleobases of natural nucleic acids, enabling information storage and base-pairing with DNA and RNA.
• The chemical diversity of XNA backbones includes sugar-modified variants (HNA, TNA, LNA, FANA, CeNA), phosphodiester linkage variants (phosphorothioates, phosphoramidates), and the radically different peptide nucleic acid (PNA) backbone.
• XNA oligomers are synthesized chemically by solid-phase phosphoramidite chemistry, with coupling efficiencies generally lower than for DNA, and enzymatically using engineered polymerases that can incorporate XNA triphosphates.
• The replication of XNAs relies on engineered polymerases obtained through directed evolution, typically using a two-step DNA→XNA→DNA cycle; error rates are higher than for natural DNA replication but sufficient for in vitro evolution.
• XNA duplex stability and geometry vary widely depending on the backbone, with LNA and PNA exhibiting particularly high thermal stability and HNA and TNA adopting distinct helical conformations.
• XNA aptamers and XNAzymes can be isolated by in vitro selection, demonstrating that non-natural backbones can support both molecular recognition and catalysis.
• Practical applications of XNAs include antisense therapeutics, aptamer-based diagnostics, and data storage, with nuclease resistance being a key advantage over natural nucleic acids.
• Successful XNA research requires careful attention to solubility, polymerase fidelity, and the choice of backbone appropriate for the intended application.

Further Reading

• Tu T et al. Functional Xeno Nucleic Acids for Biomedical Application. Chemical research in Chinese universities. 2022. PubMed 35814030
• Kowalski K. Synthesis and chemical transformations of glycol nucleic acid (GNA) nucleosides. Bioorganic chemistry. 2023. PubMed 37871392
• Mana T et al. XNAs: A Troubleshooter for Nucleic Acid Sensing. ACS omega. 2022. PubMed 35571783
• Murayama K, Asanuma H. Design and Hybridization Properties of Acyclic Xeno Nucleic Acid Oligomers. Chembiochem : a European journal of chemical biology. 2021. PubMed 33998765
• Wang Q et al. Molecular beacons of xeno-nucleic acid for detecting nucleic acid. Theranostics. 2013. PubMed 23781286
• Hu J et al. Paper-based point-of-care test with xeno nucleic acid probes. Biotechnology and bioengineering. 2019. PubMed 31282991

Related Topics

• Nucleotide Nucleic Acid
• Protein Engineering
• DNA Origami

Related Clinical & Scientific Guides

• MAPK Pathway: Mechanism, Function, and Clinical Relevance
• Mammalian Cell Culture Bioreactors: A Practical Guide
• Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks